# of Displayed Technologies: 10 / 48

Applied Category Filter (Click To Remove): Therapeutics


Categories

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Kudryashova, Elena
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Treatment of Multiple Sclerosis with small molecule IL-6/STAT3 inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Flammang, Ann Marie

Method for treatment of diseases of central nervous system (CNS) and improvement of cognitive function by nanoscaffolds
TS-038406 — A novel method to improve CNS metabolism and overall cognitive function as well as reduce peripheral neurodeneration, through the use of nanomatrices with or without identified redefined delivery biologicals and/or insulin.
The central nervous system (CNS) can be implicated in a broad category of diseases in which the brain does not function as expected. Conditions may result from a metabolic disorder; damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or…
  • College: College of Arts & Sciences
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

A novel STK1-targeted small molecule as an "antibiotic resistance breaker"
TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.
Highly pathogenic and multidrug-resistant Staphylococcus aureus (MDRSA) encompasses methicillin-resistant strains of S. aureus that have developed resistance to multiple traditional antibiotics. Because of the recent emergence of antimicrobial resistance, MDRSA has been commonly incriminated in a …
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Paschall, Christopher

Oral cancer chemopreventive rinse
TS-037788 — Rinses with sustained contact time and field coverage have been developed to prevent oral cancer.
Oral cancer affects nearly 50,000 Americans each year and has a five year survival rate of 57%. Often, oral cancer is only discovered when it has metastasized, as it does not present recognizable symptoms, and it has a high risk of producing secondary tumors. Oral squamous cell carcinoma (OSCC), a…
  • College: College of Dentistry
  • Inventors: Mallery, Susan; Lahann, Joerg
  • Licensing Officer: Paschall, Christopher

Use of Gene Product to Treat Nerve Injury and Sarcopenia
TS-037778 — A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia
Sarcopenia, the age-related wasting and loss of strength, is an important neuromuscular problem of aging. It affects up to 50% of individuals by the 8th decade, and can lead to impaired mobility, loss of independence, and increased risk of mortality. The neuromuscular system is comprised of groups…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Arnold, William; Kaspar, Brian; McGovern, Vicki
  • Licensing Officer: Flammang, Ann Marie

Thermogenic Compositions and Methods
TS-037747 — Biologicals for treatment of obesity related disease, including glucose intolerance and neurological disorders.
Worldwide obesity has tripled over the last 40 years and the incidence of overweight or obese populations is rising in low, middle, and high income countries. An increase in adipose tissue results in higher risk for cardiovascular disease and type 2 diabetes, which increase risk for Alzheimer&rsqu…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Thermogenic Biologicals Treatment of Obesity and Improvement of Insulin Resistance
TS-037746 — Innovative thermogenic biologicals, methods of delivery, and combinational therapy for the treatment of abdominal obesity
Obesity as a result of an increase in intra-abdominal (or visceral) fat is an independent risk factor for major diseases such as type 2 diabetes and cardiovascular diseases due to increases in insulin resistance and chronic inflammation. Accumulation of intra-abdominal fat, even in non-­obese …
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Antisense Oligonucleotide Development for Treatment of Spinal Muscular Atrophy
TS-037741 — The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.
Spinal muscular atrophy (SMA) is a genetic disorder that affects the control of muscle movement. It is caused by a loss of motor neurons in the spinal cord and brainstem, leading to weakness and atrophy in the muscles used for walking, crawling, sitting up, and head movement. In severe instances, …
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; McGovern, Vicki; Prior, Thomas
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

PDF

Loading icon